Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer

Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer

Triple negative breast cancer (TNBC) is a heterogeneous group of tumors which lack estrogen receptor, progesterone receptor, and HER2 expression. Targeted therapies have limited success in treating TNBC, thus a strategy enabling effective targeted combinations is an unmet need. To tackle these chall...

詳細記述

書誌詳細
主要な著者: Alkhatib, Heba, Conage-Pough, Jason, Roy Chowdhury, Sangita, Shian, Denen, Zaid, Deema, Rubinstein, Ariel M., Sonnenblick, Amir, Peretz-Yablonsky, Tamar, Granit, Avital, Carmon, Einat, Kohale, Ishwar N., Boughey, Judy C., Goetz, Matthew P.
その他の著者: Massachusetts Institute of Technology. Department of Biological Engineering
フォーマット: 論文
言語:English
出版事項: BioMed Central 2024
オンライン･アクセス:https://hdl.handle.net/1721.1/153400

インターネット

https://hdl.handle.net/1721.1/153400

類似資料